JBMR plus

JBMR Plus · ISSN (e) 2473-4039 · 1 paper in corpus

article 2020

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population

doi:10.1002/jbm4.10401 ·PMID:33354641

ABSTRACT Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed …